Novartis and the non-profit Medicines for Malaria Venture (MMV) have advanced a novel drug combination for malaria into a phase 3 programme, raising hopes of a regimen that could be used to treat ...

Between 2001 and 2009, a total of 300 million malaria treatments of Coartem, a highly effective artemisinin-based combination therapy, were delivered by Novartis, saving an estimated 750,000 lives ...

Malaria is a mosquito-borne disease that is caused by Plasmodium parasites. Patients with malaria experience flu-like symptoms and, in severe cases, the disease can progress to neurological ...

Engineering strategies to improve terpenoids’ production in Bacillus subtilis mainly focus on 2C-methyl-d-erythritol-4-phosphate (MEP) pathway overexpression. To systematically engineer the chassis ...